HIV Protease Inhibitor Report NEW!
Community Education Series on Emerging Issues on HIV/AIDS Therapies
By Jules Levin, Executive Director of NATAP

---

Introduction

Proceedings to the Community Symposium on Protease Inhibitors: Current and Future Use

A Special Report of the Third Conference on Retroviruses and Opportunistic Infections

The FDA Antiviral Advisory Committee Meeting

The XIth International Conference on AIDS

The XIth International Conference on AIDS and the 36th Interscience Conference on Antimicrobial
  Agents and Chemotherapy (ICAAC)

The Third International Congress of Drug Therapy in HIV Infection (Birmingham, England)

Appendix A: Leading HIV-1 Protease Inhibitors

Appendix B: Selected Characteristics of Leading HIV-1 Protease Inhibitors

Appendix C: Mutations in HIV-1 Protease Associated with Drug Resistance

---

This document was written by Jules Levin, Executive Director of NATAP

Go to the Protease Inhibitor Menu

Go to the Treatment Menu

Go to the HIVpositive.us Main Menu

39